BioXcel Presents Promising Data Demonstrating BXCL701 / Anti-PD1 Combination Increases Anti-Tumor Cytokines and Tumor Growth Inhibition at 2017 AACR Annual Meeting

Next-Generation Small Molecule Checkpoint Inhibitor Targeting Castration-Resistant Prostate Cancer BRANFORD, CT., April 3, 2017 – BioXcel, a biopharmaceutical company integrating big data analytics and machine learning-based artificial intelligence (AI) with drug development expertise to advance the next wave of medicines, Read More

Leave a Reply

Your email address will not be published.